Lars Bruening, CEO, Bayer UK & Ireland
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Address: No. 2, 32 Caxton Road,
Shepherd’s Bush, London W12 8AJ,United Kingdom
Tel: +44 (0)20 ‐ 7229 4552
Web: http://www.dwlanguages.com/page.asp?node=2
DWL is a specialist translation service provider for the pharmaceutical industry providing Medical Translation into all European Union (EU) and European Economic Area (EEA) languages and many others – mainly “from” and “into” English
Established in 1962, our business has grown through dedication and commitment to quality and service. This is acknowledged by our many long-standing clients and is perhaps most clearly demonstrated by their recommendation of DWL to others.
By recognising the specific needs of this market, DWL delivers a quality Medical Translation Service due to its expertise in selecting the most suitable linguists in combination with reliable project management and quality control. We understand the need to be flexible and responsive in our service, and that accuracy and thoroughness remain essential – even within the tightest of project timelines.
DW Languages provides translation solutions for the following areas:
Medical translation services
Pharmaceutical translation
Regulatory affairs
Clinical trials
Medical research and manufacturing
Legal documentation
Medical publishing and marketing communications
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed…
Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James…
Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse…
With a strong historic footprint in Edinburgh, Canon Medical Systems has based one of its global R&D centres in Scotland from where it develops software for its devices. Ken Sutherland,…
After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR…
Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and…
See our Cookie Privacy Policy Here